Women Benefit More From Implantable Defibrillators Than Men
TUESDAY, Sept. 2, 2025 -- There is a lower risk of one-year ventricular arrhythmias or death in women with nonischemic cardiomyopathy and an implantable cardioverter defibrillator (ICD) compared with men, according to a study published in the August issue of eClinicalMedicine.
Valentina Kutyifa, M.D., Ph.D., from University of Rochester Medical Center in New York, and colleagues conducted a prespecified interim analysis of the BIO-LIBRA study to assess characteristics, medical therapy, and ventricular tachyarrhythmias (VT/VF) or mortality at 12 months in 1,000 patients with nonischemic cardiomyopathy and ICD or a cardiac resynchronization therapy defibrillator (CRT-D).
The researchers found that women had a lower risk for VT/VF or death versus men through 12 months (hazard ratio [HR], 0.49), driven by a lower risk for VT/VF (HR, 0.46). These associations persisted even after adjustments for left ventricular ejection fraction or QRS duration. There were no significant differences reported by ICD versus CRT-D.
"This is the first study that had a large enough number of females enrolled to show this difference," Kutyifa said in a statement. "We learned that patients with nonischemic cardiomyopathy do well with these devices, but they still have a residual risk of developing life-threatening ventricular arrhythmias or dying, and this risk is lower in females."
Several authors disclosed ties to BIOTRONIK, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Nonoptimal Levels of Traditional Risk Factors Almost Universal Before CVD
MONDAY, Sept. 29, 2025 -- Almost all adults have nonoptimal levels of one or more traditional risk factors before being diagnosed with cardiovascular disease (CVD), according to a...
Prevention Strategies Developed for Cardiovascular Manifestations of COVID
FRIDAY, Sept. 26, 2025 -- Prevention strategies for cardiovascular manifestations of acute and long COVID are discussed in a report published online Sept. 18 in the European...
Cocoa Extract Supplementation Yields Significant Reduction in hsCRP
WEDNESDAY, Sept. 24, 2025 -- Cocoa extract supplementation yields a significant reduction in high-sensitivity C-reactive protein (hsCRP) and an increase in interferon-&gamma...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.